|
Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC). |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Medivation (Inst); Progenics (Inst); Sotio (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline (I) |
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - Saladax Biomedical |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst); Saladax Biomedical (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst) |
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst) |
|
|
No Relationships to Disclose |